P306 Serum tryptophan metabolites as a biomarker for disease severity in patients with IBD

Abstract Background The levels of tryptophan (TRP) metabolites such as kynurenine (KYN), kynurenic acid (KYNA), quinaldic acid, 3-hydrocynynene, anthranilic picolinic (PA) and xanthurenic were determined systematically in inflammatory bowel disease (IBD). Previous studies found a negative correlation with TRP IBD activity. However, there is no data about serum their severity IBD. We aimed to determine the between TRP, its clinical, laboratory, endoscopic findings activation including fecal calprotectin. Methods A total 115 patients, 77 (66.4%) UC 38 (33.6%) CD, included. Forty three % (n=49) patients female. 57 (n=66) male. mean age females males 42.07±13.39 44.23± 10.04 years, respectively. Patients categorized according activity: Sixty-five (57%) remission 50 (43%) active. predictive value activity was evaluated by tryptophan, calprotectin levels. Results At cut-off ≤11328.41 ng/ml sensitivity predict 76.9% specificity 71.7%. On other hand, at ≥89.60 µg/g calprotectin, detecting 88.1% 80.0%. Calprotectin, sedimentation, CRP, KYN/TRP values be significantly higher active period than (p<0.001, p<0.001, p<0.007 respectively). KYNA, PA statistically lower phase compared those (p=0.01, p=0.022 Conclusion Serum increased Quinolinic did not differ remission. which metabolite degradation, disease. still had superior for Further are needed assess pathway course